secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086074
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q2 rev +6% to $1,004M; EPS $2.44; cuts FY guidance on litigation charge
-----------------------------------------------------------------------------

- Revenue $1,004M, +6% reported (+7% organic); CAG Diagnostics recurring +6% reported (+7% organic).
- EPS $2.44, down 9% reported; comparable +15% excluding $0.56/share discrete litigation accrual.
- Record Q2 premium instrument placements; global premium instrument installed base grew 11% YoY.
- FY2024 guidance updated: revenue $3,885M-$3,945M (6.2-7.8% organic); EPS $10.31-$10.59, down $0.56 at midpoint.
- $62M discrete litigation expense accrual hit operating margin by ~610 bps and EPS by $0.56.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465924086074/0001104659-24-086074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465924086074/tm2420913d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer